Safety and Tolerability of Long-Term Treatment with Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Treatment-emergent adverse events for patients receiving darolutamide for a median of 38 months are described in this pooled analysis of individual patient data from Phase I/II studies.